The efficacy and safety of Cangfu Daotan decoction in the treatment of infertility associated with polycystic ovary syndrome: a systematic review and meta-analysis
Abstract
Background: Polycystic ovary syndrome (PCOS) is a common endocrine disorder characterized by ovulatory dysfunction and hormonal imbalance, often leading to infertility. Cangfu Daotan Decoction (CFDTT, Atractylodis Rhizoma, Cyperi Rhizoma, Pinelliae Rhizoma, Poria, Pericarpium Citri Reticulatae, Glycyrrhizae Radix et Rhizoma, Arisaema cum Bile, Aurantii Fructus) is a traditional Chinese herbal formula commonly used to treat PCOS-related infertility, with its pathogenesis attributed to phlegm-dampness obstruction. There is an urgent need for a systematic evaluation of its efficacy and safety.
Objective: To evaluate the efficacy, safety, and potential mechanisms of CFDTT in treating PCOS-related infertility, providing evidence for clinical application and future research.
Methods: Seven databases were searched to identify randomized controlled trials (RCTs) evaluating CFDTT for PCOS-related infertility. Data were analyzed using meta-analysis, subgroup analysis, sensitivity analysis, publication bias testing (funnel plot, Egger's test, trimming and filling method), and evidence quality assessment (GRADE).
Results: A total of 19 RCTs involving 2,181 participants were identified. CFDTT combined with conventional pharmacotherapy was superior to conventional pharmacotherapy alone in improving ovulation rate, pregnancy rate, ovarian volume, dominant follicle count, and endometrial thickness. However, due to high heterogeneity and methodological limitations, the overall certainty of…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 2,181 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.